Drugs / BAL2420
last change Apr 2026 re-read 3 minutes ago

BAL2420

also known as BAL0302420
Investigated by
Basilea Pharmaceutica · CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07500181 Mar 2026 → Jun 2027 expected — Basilea Pharmaceutica Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BAL2420 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500181 ↗
Known as BAL0302420 “BAL2420 (also known as BAL0302420) is being developed as an antibacterial agent for the treatment of severe infections caused by Gram-negative bacteria.” NCT07500181 ↗
Route Intravenous “Single intravenous (IV) dose of BAL2420 or placebo will be administered to healthy subjects” NCT07500181 ↗